SCHEMBL4076197

SCHEMBL4076197

C=CCN(C)C[C@@H](C)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4474143 1.00
SCHEMBL4598144 1.00
SCHEMBL3861417 0.83
Bromide SCHEMBL5889217 0.81 PYCR1 (0.34)
Hydrochloric Acid SCHEMBL3083723 0.81 PYCR1 (0.34)
SCHEMBL13635634 0.80
SCHEMBL4492753 0.79 TYMP (0.36)
SCHEMBL19621660 0.79 PYCR1 (0.33)
SCHEMBL5624068 0.79 TYMP (0.36)
SCHEMBL19599785 0.79 PYCR1 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7625908-B2 Quinazoline derivatives ASTRAZENECA AB (SE) 2009-12-01 US disclosed
US-20090221616-A1 QUINAZOLINE DERIVATIVES AS EGF AND/OR ERBB2 TYROSINE KINASE INHIBITORS ASTRAZENECA AB (SE) 2009-09-03 US disclosed
EP-1877398-B1 QUINAZOLINE DERIVATIVES AS EGF AND/OR ERBB2 TYROSINE KINASE INHIBITORS ASTRAZENECA AB (SE) 2009-08-05 EP disclosed
EP-1877397-B1 QUINAZOLINE DERIVATIVES AS INHIBITORS OF EGF AND/OR ERBB2 RECEPTOR TYROSINE KINASE ASTRAZENECA AB (SE) 2009-08-05 EP disclosed
US-20090023759-A1 Quinazoline Derivatives as Inhibitors of EGF and/or erbB2 Receptor Tyrosine Kinase ASTRAZENECA AB (SE) 2009-01-22 US disclosed
US-20070244136-A1 Quinazoline Derivatives ASTRAZENECA AB (SE) 2007-10-18 US disclosed
EP-1685116-A1 QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2006-08-02 EP disclosed
WO-2005051923-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2005-06-09 WO disclosed